Skip to main content
. Author manuscript; available in PMC: 2017 Dec 19.
Published in final edited form as: Gravit Space Res. 2017 Jul;5(1):2–23.

Figure 6. CDR3 AA sequence usage among treatment groups.

Figure 6

(A) Top five most common heavy chain CDR3 AA sequence usage is presented as percent of repertoire. (B) Top five most common heavy chain CDR3 AA sequence usage is presented by rank. Dark red indicates higher rank moving to white, of lower rank. An x denotes that the AA sequence was not found. (C) Unique heavy chain CDR3 AA sequences identified within and among treatment groups. (D) Top five most common kappa chain CDR3 AA sequence usage is presented as percent of repertoire. (E) Top five most common heavy chain CDR3 AA sequence usage is presented by rank. (F) Unique heavy chain CDR3 AA sequences identified within and among treatment groups.